The industry standard from hit identification to development candidate nomination is on average 33–36 months. Charles River’s truly integrated drug discovery programs have reduced this timeline to as little as 24 months through industry experienced, multi-disciplinary teams focused on resource efficiency, scientific excellence and strategic partnerships with clients through all aspects of drug discovery. With numerous technologies for hit identification, coupled with our knowledge-based approach to advance compounds from hit-to-lead into lead optimization, our integrated research teams consistently convert leads into successful preclinical development candidates.
John Montana, PhD, executive director of integrated drug discovery, discusses the difference between an integrated drug discovery project and a traditional outsourcing project.
Designing a Novel Cancer Drug—From Hit ID to Candidate
Discover how our multidisciplinary approach to hit ID, design and synthesis of novel chemical templates and development of targeted in vitro and in vivo assays resulted in the nomination of a novel cancer development candidate in just over two years. Watch Webinar Replay »